HFM
AVDL

Hartford Financial Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Hartford Financial Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$21.6K – 347
2025
Q4 		$21.6K Hold
1,000
– – 0.01% 237
2025
Q3 		$15.3K Hold
1,000
– – ﹤0.01% 254
2025
Q2 		$8.85K Sell
1,000
-500
-33% -$4.39K ﹤0.01% 285
2025
Q1 		$11.7K Hold
1,500
– – ﹤0.01% 284
2024
Q4 		$15.8K Hold
1,500
– – ﹤0.01% 275
2024
Q3 		$19.7K Hold
1,500
– – ﹤0.01% 269
2024
Q2 		$21.1K Buy
1,500
+500
+50% +$8.15K ﹤0.01% 270
2024
Q1 		$16.9K Hold
1,000
– – ﹤0.01% 285
2023
Q4 		$14.1K Hold
1,000
– – ﹤0.01% 292
2023
Q3 		$10.3K Hold
1,000
– – ﹤0.01% 301
2023
Q2 		$16.5K Hold
1,000
– – ﹤0.01% 256
2023
Q1 		$9.16K Hold
1,000
– – ﹤0.01% 285
2022
Q4 		$7.16K Hold
1,000
– – ﹤0.01% 296
2022
Q3 		$5K Hold
1,000
– – ﹤0.01% 309
2022
Q2 		$2K Hold
1,000
– – ﹤0.01% 350
2022
Q1 		$7K Buy
+1,000
New +$6.87K ﹤0.01% 308

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Hartford Financial Management's AVDL Position: Q1 2026 in Review

Hartford Financial Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,000 shares — an estimated $21.6K sold.

Hartford Financial Management first reported a position in AVDL in Q1 2022 and held it in 16 quarters. The position peaked at $21.6K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Hartford Financial Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hartford Financial Management sold 1,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $21.6K.
  • Hartford Financial Management first reported a position in Avadel Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Hartford Financial Management's Avadel Pharmaceuticals position peaked at $21.6K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Hartford Financial Management's 13F filing for Q1 2026, filed 16 Apr 2026.